RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Exploration of bacterial lipopolysaccharide-related genes signature based on T cells for predicting prognosis in colorectal cancer.
Exploration of bacterial lipopolysaccharide-related genes signature based on T cells for predicting prognosis in colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
微生物通过 LPS 相关基因刺激 T 细胞,与肿瘤微环境密切相关,从而影响 CRC 的进展和免疫应答。TALRGs 特征有助于预测 CRC 的预后和免疫治疗,并成为 CRC 新的治疗靶点和生物标志物。
肿瘤内微生物参与结直肠癌(CRC)的进展和免疫治疗。然而,由于技术限制,微生物对CRC的影响尚未被完全了解。因此,我们对细菌脂多糖(LPS)相关基因与免疫细胞之间的关系进行了系统分析,以探索预测CRC预后的新生物标志物。
采用单细胞RNA测序数据和比较毒理基因组学数据库筛选T细胞相关的LPS相关基因(TALRGs)。随后,我们在癌症基因组图谱结肠腺癌(TCGA-COAD)队列和GSE39582队列中建立并验证了TALRGs风险特征。此外,我们比较了高风险组和低风险组在肿瘤浸润免疫细胞类型、免疫治疗反应、体细胞突变谱和肿瘤突变负荷(TMB)方面的差异。另外,我们还对接受抗PD-L1药物治疗的免疫治疗队列(Imvigor210)进行了分析,以探索TALRGs特征在免疫治疗中的潜在价值。
鉴定并筛选出5个预后TALRGs用于构建预后模型。高风险组在TCGA-COAD队列(P < 0.0001)和GSE39582队列(P = 0.00019)中均预后不良。计算了TALRGs signature的曲线下面积(AUCs)(TCGA-COAD队列:1年时为0.624,3年时为0.639,5年时为0.648;anti-PD-L1队列为0.59)。高风险组在TCGA-COAD队列和GSE39582队列中均具有更晚的病理分期和更高的TMN分期。高风险组具有更高的免疫抑制细胞浸润、免疫检查点分子表达、化疗药物IC50值以及TP53突变率(P < 0.05)。此外,高TMB患者预后更差(P < 0.05)。进一步地,Imvigor210也显示高风险评分患者预后不良(铂类治疗队列:P = 0.0032;非铂类治疗队列:P = 0.00017)。
The intratumoral microorganisms participates in the progression and immunotherapy of colorectal cancer (CRC). However, due to technical limitations, the impact of microorganisms on CRC has not been fully understood. Therefore, we conducted a systematic analysis of relationship between bacterial lipopolysaccharide (LPS)-associated genes and immune cells to explore new biomarkers for predicting the prognosis of CRC.
The single-cell RNA sequencing data and the Comparative Toxicogenomics Database were used to screen T cells-associated LPS-related genes (TALRGs). Then, we established and validated the TALRGs risk signature in The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) cohort and GSE39582 cohort. Besides, we compared the differences in tumor-infiltrating immune cell types, immunotherapeutic response, somatic mutation profiles, and tumor mutation burden (TMB) between high-risk group and low-risk group. In addition, the immunotherapeutic cohort (Imvigor210) treated with an anti-PD-L1 agent was performed to explore the potential value of the TALRGs signature on immunotherapy.
Five prognostic TALRGs were identified and selected to build the prognostic model. The high-risk group had poor prognosis in both TCGA-COAD cohort ( P < 0.0001) and GSE39582 cohort ( P = 0.00019). The areas under the curves (AUCs) of TALRGs signature were calculated (TCGA-COAD cohort: 0.624 at 1 years, 0.639 at 3 years, 0.648 at 5 years; anti-PD-L1 cohort was 0.59). The high-risk group had advanced pathological stages and higher TMN stages in both TCGA-COAD cohort and GSE39582 cohort. The high-risk group had the higher infiltration of immunosuppressive cells, the expressions of immune checkpoint molecules, the IC50 values of chemotherapy drugs, and TP53 mutation rate ( P < 0.05). In addition, patients with high TMB had worse prognosis ( P < 0.05). Furthermore, the Imvigor210 also showed patients with high-risk scores had poor prognosis (platinum-treated cohort: P = 0.0032; non-platinum-treated cohort: P = 0.00017).
Microorganisms are closely related to the tumor microenvironment to influence the progression and immune response of CRC via stimulating T cells through LPS-related genes. The TALRGs signature contributed to predict the prognosis and immunotherapy of CRC, and became new therapeutic targets and biomarkers of CRC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。